Navigation Links
New Analysis Shows Potential Cost Savings of Adding Antiepileptic Drug Vimpat® C-V
Date:5/31/2011

of the medicine. Prolongations in PR interval with lacosamide have been observed in clinical studies. Cases with second and third degree AV block associated with lacosamide treatment have been reported in post-marketing experience. Lacosamide should be used with caution in patients with known conduction problems or severe cardiac disease such as a history of myocardial infarction or heart failure. Caution should especially be exerted when treating elderly patients as they may be at an increased risk of cardiac disorders or when lacosamide is used in combination with products known to be associated with PR prolongation. Second degree or higher AV block has been reported in post-marketing experience. In the placebo-controlled trials of lacosamide in epilepsy patients, atrial fibrillation or flutter were not reported; however both have been reported in open-label epilepsy trials and in post-marketing experience. Patients should be made aware of the symptoms of second-degree or higher AV block (e.g. slow or irregular pulse, feeling of lightheaded and fainting) and of the symptoms of atrial fibrillation and flutter (e.g. palpitations, rapid or irregular pulse, shortness of breath). Patients should be counseled to seek medical advice should any of these symptoms occur. Suicidal ideation and behavior have been reported in patients treated with anti-epileptic agents. Therefore patients should be monitored for signs of suicidal ideation and behaviors and appropriate treatment should be considered. Patients (and caregivers of patients) should be advised to seek medical advice should signs of suicidal ideation or behavior emerge. Lacosamide syrup contains sodium methylhydroxybenzoate (E219), which may cause allergic reaction (possibly delayed). Patients with rare hereditary problems of fructose intolerance should not take this medicine. The syrup contains aspartame (E951), a source of phenylalanine, which may be harmful for people with phenylketonuria. Both the syrup and solut
'/>"/>
SOURCE UCB
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Reportlinker Adds Greece Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2017
2. Reportlinker Adds Global Top 10 Pharmaceutical Companies: Industry, Financial and SWOT Analysis
3. Reportlinker Adds Triple Analysis: Colorectal Cancer, Lymphoma and Peptides
4. Reportlinker Adds Triple Analysis: Lymphoma, Pancreatic Cancer and Prostate Cancer
5. Reportlinker Adds Triple Analysis: Lymphoma, Prostate Cancer and Antibodies
6. Reportlinker Adds Triple Analysis: Colorectal Cancer, Lymphoma and Pancreatic Cancer
7. Reportlinker Adds United Arab Emirates Neurology Devices Investment Opportunities, Analysis and Forecasts to 2017
8. Reportlinker Adds Triple Analysis: Lung Cancer, Lymphoma and Angiogenesis
9. Reportlinker Adds Triple Analysis: Lymphoma, Melanoma and Peptides
10. Reportlinker Adds Triple Analysis: Leukemia, Lymphoma and Peptides
11. Reportlinker Adds Global Water Market Outlook: Strategic Analysis of Water and Wastewater Management in the Pharmaceutical Industry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Dec. 23, 2014 Echo Therapeutics, Inc. ... company focused on skin permeation, continuous glucose monitoring ... W. Hollander has been appointed Chief Executive ... more than 20 years of experience in the ... most recently served as Vice President, Business Development, ...
(Date:12/24/2014)... , Dec. 23, 2014 ResMed (NYSE: ... patent infringement action against Chinese medical device manufacturer BMC Medical ... ruled today that BMC,s masks listed below infringe ResMed,s patents, ... selling these masks in the United States ... N2 nasal mask , Willow nasal pillows mask ...
(Date:12/24/2014)... 23, 2014   Synageva BioPharma Corp. ... developing therapeutic products for rare disorders, today announced ... the Marketing Authorization Application (MAA) for sebelipase alfa ... company,s request for accelerated assessment, which has the ... The MAA, and the Biologics ...
Breaking Medicine Technology:Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 2Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 3ResMed Wins Patent Infringement Lawsuit Against Chinese Manufacturer BMC Medical 2Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 2Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 3
... AMRI (NASDAQ: AMRI ), a leading ... appointment of Ian Shott as President of AMRI Europe, ... In this newly created role, Mr. Shott will have ... company,s site in Wales, United Kingdom, and work closely ...
... SALT LAKE CITY, May 22, 2012   USANA Health ... global nutritional supplement company, today announced the promotion of ... and development and Dr. Brian Dixon to executive director ... Steely, a licensed naturopathic physician, Mark Levy, a Ph.D. ...
Cached Medicine Technology:AMRI Announces President for AMRI Europe 2AMRI Announces President for AMRI Europe 3USANA Health Sciences Expands Award-Winning Research and Development Team 2USANA Health Sciences Expands Award-Winning Research and Development Team 3
(Date:12/26/2014)... 2014 DW-InductionHeating.com (DaWei Induction Heating Co.) ... and developing, producing and marketing of a series of ... announces their new series of induction brazing equipments ... company, induction brazing refers to the joining ... material and heat. The manager says that there are ...
(Date:12/25/2014)... 26, 2014 The report “Nintedanib ... 2023” focuses on the current treatment landscape, unmet ... colorectal cancer market. Stivarga is a drug which ... rectal cancer. Boehringer Ingelheim is developing nintedanib (BIBF-1120), ... of refractory CRC in the US, Europe, and ...
(Date:12/25/2014)... Recently, Dylan Queen, a famous online company supplying women’s ... discounted prom dresses, most of which are priced under ... company, the promotion is valid until Jan. 22, 2015; ... UK market. , The prom dresses in this new ... A-line strapless, empire strapless chiffon, one shoulder, floor-length, V-neck ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 When head lice ... themselves in a frenzy to get rid of it while ... families in Coral Gables now have the solution right in ... salon clinic location, Lice Troopers provides full spectrum head lice ... Coral Gable area, including Sunset, Key Biscayne, Brickell, Coconut Grove, ...
(Date:12/25/2014)... 2014 (HealthDay News) -- Among early stage breast cancer ... half of one percent will eventually develop leukemia as ... The finding comes from a review of more ... 2007, and it suggests that the risk for developing ... had previously thought. "The frequency of bone marrow ...
Breaking Medicine News(10 mins):Health News:Induction Brazing Equipment Series From DaWei Induction Heating Co., A Reliable Supplier Of Induction Heating Equipment 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:Coral Gables Florida Gets Ready to Be Lice-Free with Lice Troopers 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 3
... it has received approval from the U.S. Food and ... gum USP, 2 mg (coated fruit) and 4 mg ... marketed under store brand labels and is comparable to ... aid to smoking cessation. "This first store brand approval ...
... the advent of a possible new blockbuster drug and ... and drug addictions, global sales of smoking cessation and ... of little over $1.1 billion in 2005 to more ... and Addiction Treatments: A World Market Analysis, a new ...
... of mobile phones in the provision of clinical care are ... and Safety in Health Care argues. ,Healthcare ... to help improve the provision of care to people with ... disease. ,The UK and the US are leading ...
... Medarex, Inc. today announced a collaborative research agreement ... Chemical Holdings Corporation . The two companies expect ... against a Mitsubishi target for the potential treatment ... Medarex's UltiMAb Human Antibody Development System(R) to generate ...
... the most common addiction all over the world, and a ... impact of tobacco in its various forms on human health, ... smoking. ,Tobacco generates about Rs.7,964 crore ... about Rs.27,661 crore, according to WHO estimates. ...
... risk the wrath of the country's 350 million smokers today by ... ,"It will be applied in all Olympic venues and ... ,A sign of the passions the issue can raise ... ,Earlier this month, an attempt by security guards ...
Cached Medicine News:Health News:Perrigo Receives FDA Approval to Market Coated Fruit Nicotine Gum 2Health News:Urgent Need for Guidance on Mobile Phone Use in Clinical Care 2Health News:Tobacco Menace and What can Be Done About It 2Health News:Tobacco Menace and What can Be Done About It 3Health News:Tobacco Menace and What can Be Done About It 4Health News:China Bans Smoking at Olympics 2